Who will run the CDC temporarily?

Leadership shift puts a national infectious-disease agency under temporary oversight

Federal officials have installed the current director of the National Institutes of Health to lead the Centers for Disease Control and Prevention on an acting basis. This move consolidates leadership of two major federal health agencies in a single individual while the administration searches for a permanent director.

The temporary arrangement has immediate operational and political consequences. At a time when the nation faces multiple public‑health challenges — including outbreaks of vaccine-preventable diseases and broader questions about pandemic preparedness — placing one person in charge of both agencies concentrates decision-making authority and raises concerns about continuity, expertise, and independence. Medical societies, public-health experts, and some members of Congress have flagged the potential for conflicts in priorities and the perception that public-health guidance could shift with political leadership.

Potential near-term impacts include:

• Changes in vaccine and disease-prevention policy priorities.
• Disruptions to ongoing programs as the acting leader balances dual responsibilities.
• Heightened scrutiny from professional groups and courts over advisory processes and meetings that inform policy.

What to watch next:

• Whether the acting leader will maintain existing scientific advisory processes or pursue rapid policy changes.
• How federal public-health funding and program operations are managed across both agencies during the interim period.
• Responses from state and local health departments that rely on stable federal guidance for outbreak response.

In short, the temporary leadership consolidation is reshaping who sets national public-health priorities during an already fraught period for vaccine policy and disease control.